Adeno-associated virus expression systems for gene transfer

Current Opinion in Biotechnology

Volumn 9, Issue 5, 1998, Pages 470-475

  Rabinowitz, Joseph E ^a   Samulski, Jude ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HELICASE;

ADENO ASSOCIATED VIRUS; ANIMAL MODEL; BRAIN; CELL LINE; CLINICAL TRIAL; EXPRESSION VECTOR; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; HELPER VIRUS; HUMAN; MUSCLE; NONHUMAN; PRIORITY JOURNAL; REPORTER GENE; REVIEW; VIRUS EXPRESSION; VIRUS RECOMBINANT;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE; ANIMALIA; DNA VIRUSES;

EID: 0032190675     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0958-1669(98)80031-1     Document Type: Article

References (64)

1. Srivastava A, Lusby EW, Berns KI. Nucleotide sequence and organization of the adeno-associated virus 2 genome. J Virol. 45:1983;555-564.
2. Atchison RW, Casto BC, Hammond WM. Adenovirus-associated defective virus particles. Science. 149:1965;754-756.
3. Buller RM, Janik JE, Sebring ED, Rose JA. Herpes simplex virus type 1 and 2 completely help adenovirus-associated virus replication. J Virol. 40:1981;241-247.
4. Berns KI, Pinkerton TC, Thomas GF, Hoggan MD. Detection of adeno-associated virus (AAV)-specific nucleotide sequences in DBA isolated from latently infected Detroit 6 cells. Virology. 68:1975;556-560.
5. Samulski RJ, Chang LS, Shenk T. Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J Virol. 63:1989;3822-3828.
6. Samulski RJ, Sally M, Muzyczka N. Adeno-associated viral vectors. Friedman T. The Development of Human Gene Therapy. 1998;Cold Spring Harbor Laboratory Press, New York.
7. McLaughlin SK, Collis P, Hermonat PL, Muzyczka N. Adeno-associated virus general transduction vectors: analysis of proviral structure. J Virol. 62:1988;1963-1973.
8. Bohenzky RA, LeFebvre RB, Berns KI. Sequence and symmetry requirements within the palindromic sequences of the adeno-associated virus terminal repeat. Virology. 166:1988;316-327.
9. Samulski RJ, Srivastava A, Berns KI, Muzyczka N. Rescue of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc Natl Acad Sci USA. 79:1983;2077-2081.
10. Ferrari FK, Samulski T, Shenk T, Samulski RJ. Second strand synthesis is a rate limiting step for efficient transduction by rAAV vectors. J Virol. 70:1996;3227-3234.
11. Fisher KJ, Gao GP, Weitzman MD, DeMatteo R, Burda JF, Wilson JM. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J Virol. 70:1996;520-532.
12. Salvetti A, Oreve S, Chadeuf G, Favre D, Cherel Y, Champion Arnaud P, David-Ameline J, Moullier P. Factors influencing recombinant adeno-associated virus production. of special interest Hum Gene Ther. 9:1998;695-706 A comparison of rAAV production techniques on a large scale. With direct comparisons of particle number and infectious particle number as well as levels of wild type AAV contamination.
13. Wang XS, Srivastava A. Rescue and autonomous replication of adeno-associated virus type 2 genomes containing Rep-binding site mutations in the viral p5 promoter. J Virol. 72:1998;4811-4818.
14. Koeberl DD, Alexander IE, Halbert CL, Russell DW, Miller AD. Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors. Proc Natl Acad Sci USA. 94:1997;1426-1431.
15. Pereira DJ, McCarty DM, Muzyczka N. The adeno-associated virus (AAV) rep protein acts as both a repressor and an activator to regulate AAV transcription during a productive infection. of special interest J Virol. 71:1997;1079-1088 This paper begins to describe the complex interaction between the replication proteins of AAV and their promoters during adenovirus infection.
16. Pereira DJ, Muzyczka N. The cellular transcription factor SP1 and an unknown cellular protein are required to mediate Rep protein activation of the adeno-associated virus p19 promoter. J Virol. 71:1997;1747-1756.
17. Lewis BA, Tullis G, Seto E, Horikoshi N, Weinmann R, Shenk T. Adenovirus E1A proteins interact with the cellular YY1 transcrition factor. J Virol. 69:1995;1628-1636.
18. Shi Y, Seto E, Chang LS, Shenk T. Transcriptional repression by YY1, a human GL1-Kruppel-related protein, and relief of repression by adenovirus E1A protein. Cell. 67:1991;377-388.
19. Xiao X, Li J, Samulski RJ. Production of high-liter recombinant adeno-associated virus vectors in the absence of helper adenovirus. of outstanding interest J Virol. 72:1998;2224-2232 One of the disadvantages in the production of rAAV is the contaminating adenovirus by-product. This paper brings together new production techniques that result in high titer adenovirus free rAAV.
20. Weger S, Wistuba A, Grimm D, Kleinschmidt JA. Control of adeno associated virus type 2 cap gene expression: relative influence of helper virus, terminal repeats, and rep proteins. of special interest J Virol. 71:1997;8437-8447 The authors describe the relationship between helper virus, specific rep proteins, and rep binding element in the terminal repeats on production of capsid proteins.
21. Flotte TR, Barraza-Ortiz X, Solow R, Afione SA, Carter BJ, Guggino WB. An improved system for packaging recombinant adeno-associated virus vectors capable of in vivo transduction. Gene Ther. 2:1995;29-37.
22. Vincent KA, Piraino ST, Wadsworth SC. Analysis of recombinant adeno-associated virus packaging and requirements for rep and cap gene products. of special interest J Virol. 71:1997;1897-1905 Rous sarcoma virus long terminal repeat and CMV immediate early promoters were used in place of p5 and p40, respectively. The authors showed that increased synthesis of capsid proteins lead to an increase in rAAV titers, and that increasing rep expression decreased rAAV yeilds and capsid synthesis.
23. Li J, Samulski RJ, Xiao X. Role for highly regulated rep gene expression in adeno-associated virus vector production. of special interest J Virol. 71:1997;5236-5243 Exogenous promoters were used to increase expression of rep genes in order to determine the effect of rep on rAAV production. The result of increased rep expression was a decrease in both capsid and rAAV production. In an effort to reduce rep expression levels, a mutation in the start codon AUG to ACG was made and this resulted in higher levels of both capsid and rAAV production; further demonstrating the importance of rep regulation for rAAV production.
24. Monahan PE, Samulski RJ, Tazelaar J, Nichols TC, Bellinger DA, Read MS, Walsh CE. Direct intramuscular infection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia. Gene Ther. 5:1998;40-49.
25. Conway JE, Zolotukhin S, Muzyczka N, Hayward GS, Byrne BJ. Recombinant adeno-associated virus type 2 replication and packaging is entirely supported by a herpes simplex virus type 1 amplicon expression rep and cap. J Virol. 71:1997;8780-8789.
26. Janik JE, Huston MM, Rose JA. Locations of adenovirus genes required for the replication of adenovirus-associated virus. Proc Natl Acad Sci USA. 78:1981;1925-1929.
27. Ferrari FK, Xiao X, McCarty D, Samulski RJ. New developments in the generation of Ad-free, high-titer rAAV gene therapy vectors. of special interest Nat Med. 3:1997;1295-1297 The authors showed for the first time that rAAV can be produced using adenovirus vectors as the source of adenovirus helper function.
28. Holscher C, Horer M, Kleinschmidt JA, Zentgraf H, Burkle A, Heilbronn R. Cell lines inducibly expressing the adeno-associated virus (AAV) rep gene: requirements for productive replication of rep-negative AAV mutants. J Virol. 68:1994;7169-7177.
29. Clark KR, Voulgaropoulou F, Fraley DM, Johnson PR. Cell lines for the production of recombinant adeno-associated virus. Hum Gene Ther. 6:1995;1329-1341.
30. Tamayose K, Hirai Y, Shimada T. A new strategy for large-scale preparation of high-titer recombinant adeno-associated virus vectors by using packaging cell lines and sulfonated cellulose column chromotography. Hum Gene Ther. 7:1996;507-513.
31. Ding L, Lu S, Munshi NC. In vitro packaging of an infectious recombinant adeno-associated virus 2. of special interest Gen Ther. 4:1997;1167-1172 Potentially the safest production approach will be in vitro. The authors demonstrate for the first time the feasability of this approach.
32. Zhou Z, Muzyczka N. In vitro packaging of adeno-associated virus DNA. of special interest J Virol. 72:1998;3241-3247 A detailed analysis of the substrates required for small scale in vitro packaging of rAAV, and the different products resulting from in vitro assembly with regards to packaging size and chloroform sensitivity.
33. Ponnazhagan S, Mukherjee P, Yoder MC, Wang XS, Zhou SZ, Kaplan J, Wadsworth S, Srivastava A. Adeno-associated virus 2-mediated gene transfer in vivo: organ-tropism and expression of transduced sequences in mice. of outstanding interest Gene. 190:1997;203-210 This paper asks the question of bio-distribution of rAAV2 in mice. After tail-vein injection, PCR amplification was used to detect the presence of rAAV in various tissues at time points ranging from one hour to one week. Although the majority of the virus ends up in the liver, detectable amounts are found in other organs, including-bone marrow, heart, kidney, and lung.
34. Ali RR, Reichel MB, Thrasher AJ, Levinsky RJ, Kinnon C, Kanuga N, Hunt DM, Bhattacharya SS. Gene transfer into the mouse retina mediated by an adeno-associated viral vectors. Hum Mol Gene. 5:1996;591-594.
35. Ali RR, Reichel MB, De Alwis M, Kanuga N, Kinnon C, Levinsky RJ, Hunt DM, Bhattacharya SS, Thrasher AJ. Adeno-associated virus gene transfer to mouse retina. Hum Gene Ther. 9:1998;81-86.
36. Kaplitt MG, Leone P, Samulski RJ, Xiao X, Pfaff DW, O'Malley KL, During MJ. Long-term gene expression and phenotypic correction using adeno-associated virus vector in the mammalian brain. Nat Genet. 8:1994;148-154.
37. McCown TJ, Xiao X, Breese GR, Samulski RJ. Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector. Brain Res. 713:1996;99-107.
38. Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol. 70:1996;8098-8108.
39. Snyder RO, Miao CH, Patijn GA, Spratt SK, Danos O, Nagy D, Gown AM, Winther B, Meuse L, Cohen LK, et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Gene. 16:1997;270-276.
40. Koeberl DD, Alexander IE, Halbert CL, Russell DW, Miller AD. Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors. Proc Natl Acad Sci. 94:1997;1426-1431.
41. Lynch CM, Hara PS, Leonard JC, Williams JK, Dean RH, Geary RL. Adeno-associated virus vectors for vascular gene delivery. Circ Res. 80:1997;497-505.
42. Rolling F, Nong Z, Pisvin S, Collen D. Adeno-associated virus-mediated gene transfer into rat carotid arteries. Gene Ther. 4:1997;757-761.
43. Kessler PD, Podsakoff GM, Chen X, McQuiston SA, Colosi PC, Matelis LA, Kurtzman GJ, Byrne BJ. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci USA. 93:1996;14082-14087.
44. Lalwani A, Walsh B, Reilly P, Carvalho G, Zolotukhin S, Muzyczka N, Mhatre A. Long-term in vivo cochlear transgene expression mediated by recombinant adeno-associated virus. Gene Ther. 5:1998;277-281.
45. Rubenstein RC, McVeigh U, Flotte TR, Guggino WB, Zeitlin PL. CFTR gene transduction in neonatal rabbits using an adeno-associated virus (AAV) vector. Gene Ther. 4:1997;384-392.
46. Kaplett MG, Xiao X, Samulski RJ, Li J, Ojamaa K, Klein IL, Makimura H, Kaplitt MJ, Strumpf RK, Diethrich EB. Long-term gene transfer in porcine myocardium after coronary infusion of an adeno-associated virus vector. Ann Thorac Surg. 62:1996;1669-1676.
47. Fisher KJ, Jooss K, Alston J, Yang Y, Haecker SE, High K, Pathak R, Raper SE, Wilson JM. Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med. 3:1997;306-312.
48. During MJ, Samulski RJ, Elsworth JD, Kaplitt MG, Leone P, Xiao X, Li J, Freese A, Taylor JR, Roth RH, et al. In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector. Gene Ther. 5:1998;820-827.
49. Zhou S, Murphy JE, Escobedo JA, Dwarki VJ. Adeno-associated virus-mediated delivery of erythropoietin leads to sustained elevation of hematocrit in nonhuman primates. of special interest Gene Ther. 5:1998;665-670 The authors describe the long-term theraputic expression of monkey erythropoietin from rAAV after single intramuscular injection in baboons. This study demonstrates that rAAV can be used in a large animal model.
50. Xiao X, Li J, McCown TJ, Samulski RJ. Gene transfer by adeno-associated virus vectors into the central nervous system. Exp Neurol. 144:1997;113-124.
51. Alexander IE, Russell DW, Spence AM, Miller AD. Effects of gamma irradiation on the transduction of dividing and nondividing cells in brain and muscle of rats by adeno-associated virus vectors. Hum Gen Ther. 7:1996;841-850.
52. Bartlett JS, Samulski RJ, McCown TJ. Selective and rapid uptake of adeno-associated virus type 2 in brain. Hum Gene Ther. 9:1998;1181-1186.
53. Peel AL, Zolotukhin S, Schrimsher GW, Muzyczka N, Reir PJ. Efficient transfer of green fluorescent proteins in spinal cord neurons using adeno-associated virus vectors containing cell type-specific promoters. Gene Ther. 4:1997;16-24.
54. Xiao X, McCown TJ, Li J, Breese GR, Morrow AL, Samulski RJ. Adeno-associated virus (AAV) vectors antisense gene transfer in vivo decreases GABA(A) alpha 1 containing receptors and increases inferior collicular seizure sensitivity. Brain Res. 756:1997;76-83.
55. Mandel RJ, Spratt SK, Snyder RO, Leff SE. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc Natl Acad Sci USA. 94:1997;14083-14088.
56. Mandel RJ, Rendahl K, Spratt S, Snyder R, Cohen L, Leff S. Characterization of intrastriatal recombinant adeno-associated virus mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrogylase I in a rat model of Parkinson's disease. J Neurosci. 18:1998;4271-4284.
57. Jooss K, Yang Y, Fisher KJ, Wilson JM. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. of outstanding interest J Virol. 72:1998;4212-4223 This is an excellent paper describing the immunologic state in response to rAAVlacZ transduction in muscle cells. It asks the question why rAAV fails to elicit an immune response when other vector systems do. Adoptive transfer experiments clearly indicate the antigen-presenting cells activated by adenovirus lacZ will eliminate lacZ expressing muscle cells previously infected with rAAVlacZ.
58. Herzog RW, Hagstrom JN, Kung S-H, Tai SJ, Wilson JM, Fisher KJ, High KA. Stable gene transfer and expression of human coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci USA. 94:1997;5804-5809.
59. Clark KR, Sferra TJ, Johnson PR. Recombinant adeno-associated viral vectors mediate long-term transgene expression in muscle. Hum Gene Ther. 8:1997;659-669.
60. Snyder RO, Spratt SK, Lagarde C, Bohl D, Kaspar B, Sloan B, Cohen LK, Danos O. Efficient and stable adeno-associated virus-mediated tranduction in the skeletal muscle of adult immunocompetent mice. Hum Gene Ther. 8:1997;1891-1900.
61. Fisher KJ, Jooss K, Alston J, Yang Y, Haecker SE, High K, Pathak R, Raper SE, Wilson JM. Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med. 3:1997;306-312.
62. Murphy JE, Zhou S, Giese K, Williams LT, Escobedo JA, Dwarki VJ. Long-term correction of obesity and dabetes in genetically obese mice by a single intramuscular injection of recombinant adeno-associated virus encoding mouse leptin. of outstanding interest Proc Natl Acad Sci USA. 94:1997;13921-13926 This paper illustrates the potential of rAAV carrying a theraputic for the correction of leptin deficiency in mice. Long-term expression of the leptin gene over a period of 180 days with a range of serum levels between 50-125% of normal. Treated mice showed decreases in food intact and weight, as well as normal glucose levels.
63. Muzzin P, Eisensmith RC, Copeland KC, Woo SL. Correction of obesity and diabetes in genetically obese mice by leptin gene therapy. Proc Natl Acad Sci USA. 93:1996;14804-14808.
64. Wang X, Khuntirat B, Qing K, Ponnazhagan S, Kube D, Zhou S, Dwarki Z, Srivastaba A. Characterisation of wild-type adeno-associated virus type 2-like particles generated during recombinant viral vector production and strategies for their elimination. J Virol. 72:1998;5472-5480.